Pentostatin therapy of T-cell lymphomas with cutaneous manifestations

Journal of Clinical Oncology

Volumn 17, Issue 10, 1999, Pages 3117-3121

  Kurzrock, Razelle ^a   Pilat, Susan ^a   Duvic, Madeleine ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PENTOSTATIN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; DRUG TOLERABILITY; FEMALE; GRANULOCYTOPENIA; HERPES ZOSTER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE COUNT; MALE; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; SKIN LYMPHOMA; T CELL LYMPHOMA; TREATMENT OUTCOME;

EID: 0032888693     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1999.17.10.3117     Document Type: Article

References (16)

1. Willemze R, Kerl H, Sterry W, et al: EORTC classification for primary cutaneous lymphomas: A proposal from the cutaneous lymphoma study group of the European organization for research and treatment of cancer. Blood 90:354-371, 1997
2. Harris NL, Jaffe ES, Stein H, et al: A revised European-American classification of lymphoid neoplasms: A proposal from the international lymphoma study group. Blood 84:1361-1392, 1994
3. Diamandidou E, Cohen PR, Kurzrock R: Mycosis fungoides and Sézary syndrome. Blood 88:2385-2409, 1996
4. Grever MR, Siaw MF, Jacob WF, et al: The biochemical and clinical consequences of 2′-deoxycoformycin in refractory lymphoproliferative malignancy. Blood 57:406-417, 1981
5. De Korte D, Haverkort WA, Van Leeuwen EF, et al: Biochemical consequences of 2′-deoxycoformycin treatment in a patient with T-cell lymphoma. Cancer 60:750-755, 1987
6. Major PPK, Agarwal RP, Kufe DW: Clinical pharmacology of deoxycoformycin. Blood 58:91-96, 1981
7. Dearden C, Matutes E, Catovsky D: Deoxycoformycin in the treatment of mature T-cell leukaemias. Br J Cancer 64:903-906, 1991
8. Cummings FJ, Tsiatis A, O'Connell M. et al: Phase II trial of low dose 2-deoxycoformycin in refractory malignant lymphomas. Proc Am Assoc Cancer Res 27:197, 1986 (abstr)
9. Grever MR, Chapman RA, Ratanatharathorn V, et al: An investigation of deoxycoformycin in advanced cutaneous T cell lymphoma (CTCL). Clin Res 33:853A, 1985 (abstr)
10. Greiner D, Olsen EA, Petroni G: Pentostatin (2′-deoxycoformycin) in the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol 36:950-951, 1997
11. Lamberg SI, Green S, Byar D, et al: Clinical staging for cutaneous T-cell lymphoma. Ann Intern Med 100:187-191, 1994
12. Edelson R, Berger C, Gasparro F, et al: Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. N Engl J Med 316:297-303, 1987
13. Brogden RN, Sorkin EM: Pentostatin: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in lymphoproliferative disorders. Drugs 46:652-677, 1993
14. Spiers ASD, Moore D, Cassileth PA, et al: Remissions in hairy-cell leukemia with pentostatin (2′-deoxycoformycin). N Engl J Med 316:825-830, 1987
15. Kraut EH, Grever MR, Bouroncle BA: Long-term follow-up of patients with hairy cell leukemia after treatment with 2′-deoxycoformycin. Blood 84:4061-4063, 1994
16. Seymour JF, Talpaz M, Kurzrock R: Response duration and recovery of CD4+ lymphocytes following deoxycoformycin in interferon-alpha resistant hairy cell leukemia: 7-year follow-up. Leukemia 11:42-47, 1997